Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zatolmilast in PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome)
NCT06717438Phase 2Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zatolmilast in PPP2R5D-related intellectual disability, sponsored by Shionogi & Co., Ltd.. Started May 2025; status: active, not recruiting.
02
Drugs
zatolmilast
03
Conditions
PPP2R5D-related intellectual disability
Beyond the preview
Go deeper on NCT06717438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717438.